Directorio

We are doing this study to compare the results of using the study drug ASTX727 in combination with another drug called venetoclax and the results of using the study drug in combination with venetoclax and another drug called enasidenib. We want to find out which option is most likely to have a positive benefit for people with acute myeloid leukemia (AML).

We are doing this study to find out if giving patients a drug called atezolizumab before and after surgery for recurrent glioblastoma can improve how their cancer responds.

The purpose of this study is to better understand how prenatal maternal health, such as higher body mass, and well-being, such as mental health, are related to early child development. We are especially interested in identifying the factors that influence young children's ability to regulate their emotions. We hope that any new information we learn from this study could benefit young children in the years to come. El propósito de este estudio es comprender mejor cómo la salud prenatal de la madre, como una mayor masa corporal, y el bienestar, como la salud mental, están relacionados con el desarrollo tempano de los niños. Estamos especialmente interesados en identificar los factores que influyen en la capacidad de los niños pequeños para regular sus emociones. Esperamos que cualquier información nueva que obtengamos de este estudio pueda beneficiar a los niños pequeños en los años venideros.

We are doing this study to see how tucatinib, trastuzumab, and mFOLFOX6 work to treat cancer of your colon or rectum that is HER2-positive with mFOLFOX6 alone or combined with bevacizumab.

This study is being done to find out if atropine eyedrops (0.05% atropine, 99.95% inactive solution) and/or special eyeglass lenses are an effective strategy to slow down the progression of myopia for young children with nearsightedness.

We are doing this study to learn more about the differences in the muscle and blood of people that have Peripheral Arterial Disease (PAD).

We are doing this study to compare the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib. We want to find out if adding gilteritinib to the usual treatment is beneficial for people with acute myeloid leukemia (AML).

We are doing this study to find out if 2 different experimental drug combinations can improve outcomes for people who are newly diagnosed with AML. We want to compare the outcomes from the standard treatment (cytarabine + daunorubicin) to the following experimental regimens:

• Venetoclax + cytarabine + daunorubicin
• Venetoclax + azacitidine